These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 25297768)

  • 1. [Treatment of untreated multiple myeloma patients ineligible for autologous stem cell transplantation].
    Tsurumi H
    Rinsho Ketsueki; 2014 Oct; 55(10):2027-35. PubMed ID: 25297768
    [No Abstract]   [Full Text] [Related]  

  • 2. [Treatment of transplant-eligible symptomatic multiple myeloma].
    Nakaseko C
    Rinsho Ketsueki; 2014 Oct; 55(10):2016-26. PubMed ID: 25297767
    [No Abstract]   [Full Text] [Related]  

  • 3. Treatment of multiple myeloma: 2009 update.
    Prescrire Int; 2009 Dec; 18(104):263-6. PubMed ID: 20025098
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Frontline Therapy for Patients with Multiple Myeloma not Eligible for Stem Cell Transplantation.
    Moreau P; Hulin C; Facon T
    Hematol Oncol Clin North Am; 2014 Oct; 28(5):829-38. PubMed ID: 25212885
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Hematopoietic stem cell transplantation for multiple myeloma].
    Kanda Y
    Rinsho Ketsueki; 2009 Oct; 50(10):1420-6. PubMed ID: 19915350
    [No Abstract]   [Full Text] [Related]  

  • 6. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial.
    Palumbo A; Bringhen S; Rossi D; Cavalli M; Larocca A; Ria R; Offidani M; Patriarca F; Nozzoli C; Guglielmelli T; Benevolo G; Callea V; Baldini L; Morabito F; Grasso M; Leonardi G; Rizzo M; Falcone AP; Gottardi D; Montefusco V; Musto P; Petrucci MT; Ciccone G; Boccadoro M
    J Clin Oncol; 2010 Dec; 28(34):5101-9. PubMed ID: 20940200
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bortezomib plus melphalan and prednisone for multiple myeloma.
    Islam A; Ambrus JL
    N Engl J Med; 2008 Dec; 359(24):2613; author reply 2613-4. PubMed ID: 19073984
    [No Abstract]   [Full Text] [Related]  

  • 8. 10 years of experience with thalidomide in multiple myeloma patients: report of the Czech Myeloma Group.
    Minarik J; Sandecka V; Maisnar V; Gregora E; Spicka I; Starostka D; Plonkova H; Jarkovsky J; Walterova L; Wrobel M; Adamova D; Pika T; Melicharova H; Pour L; Radocha J; Pavlicek P; Straub J; Gumulec J; Bacovsky J; Adam Z; Scudla V; Hajek R
    Leuk Res; 2013 Sep; 37(9):1063-9. PubMed ID: 23845888
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Part II: role of maintenance therapy in transplant-ineligible patients.
    Palumbo A; Mina R
    J Natl Compr Canc Netw; 2013 Jan; 11(1):43-9. PubMed ID: 23307980
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of multiple myeloma in the targeted therapy era.
    Saad AA; Sharma M; Higa GM
    Ann Pharmacother; 2009 Feb; 43(2):329-38. PubMed ID: 19193585
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tandem transplants in the treatment of multiple myeloma. Pro.
    Fassas AB; Tricot G
    Clin Adv Hematol Oncol; 2004 May; 2(5):303-4. PubMed ID: 17682284
    [No Abstract]   [Full Text] [Related]  

  • 12. Induction therapy for newly diagnosed multiple myeloma.
    Lonial S; Miguel JF
    J Natl Compr Canc Netw; 2013 Jan; 11(1):19-28. PubMed ID: 23307978
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mantle cell lymphoma arising in a multiple myeloma patient responding to lenalidomide.
    Dasanu CA; Reale MA; Bauer F
    Leuk Res; 2010 Jul; 34(7):e178-80. PubMed ID: 20079532
    [No Abstract]   [Full Text] [Related]  

  • 14. [New treatment strategies for multiple myeloma].
    Ozaki S
    Rinsho Ketsueki; 2009 Oct; 50(10):1506-17. PubMed ID: 19915360
    [No Abstract]   [Full Text] [Related]  

  • 15. Frontline regimens for multiple myeloma patients.
    Lonial S
    Clin Adv Hematol Oncol; 2010 May; 8(5):331-2. PubMed ID: 20551891
    [No Abstract]   [Full Text] [Related]  

  • 16. Current therapeutic strategy for multiple myeloma.
    Suzuki K
    Jpn J Clin Oncol; 2013 Feb; 43(2):116-24. PubMed ID: 23293370
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients.
    Palumbo A; Gay F; Falco P; Crippa C; Montefusco V; Patriarca F; Rossini F; Caltagirone S; Benevolo G; Pescosta N; Guglielmelli T; Bringhen S; Offidani M; Giuliani N; Petrucci MT; Musto P; Liberati AM; Rossi G; Corradini P; Boccadoro M
    J Clin Oncol; 2010 Feb; 28(5):800-7. PubMed ID: 20048187
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bortezomib in combination with thalidomide-dexamethasone for previously untreated multiple myeloma.
    Wang M; Giralt S; Delasalle K; Handy B; Alexanian R
    Hematology; 2007 Jun; 12(3):235-9. PubMed ID: 17558699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimising bortezomib in newly diagnosed multiple myeloma.
    Rajkumar SV
    Lancet Oncol; 2010 Oct; 11(10):909-10. PubMed ID: 20739219
    [No Abstract]   [Full Text] [Related]  

  • 20. First-line treatment of elderly multiple myeloma patients.
    Palumbo A
    Clin Adv Hematol Oncol; 2010 Aug; 8(8):529-30. PubMed ID: 20966887
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.